<DOC>
	<DOCNO>NCT01035424</DOCNO>
	<brief_summary>The primary aim study ass genotype - phenotype correlation CNS manifestation late infantile neuronal ceroid lipofuscinosis ( LINCL ) , fatal , rare , recessive disorder CNS child . This study accomplish compare genotype neurologic assessment Weill Cornell LINCL scale , UBDRS scale , standardize CHQ quality life scale , Mullen scale ; magnetic resonance imaging ( MRI ) ; routine clinical evaluation . This study design run parallel separate study do Department Genetic Medicine , use gene transfer treat central nervous system ( CNS ) manifestation late infantile neuronal ceroid lipofuscinosis .</brief_summary>
	<brief_title>Genotype-Phenotype Correlations Late Infantile Neuronal Ceroid Lipofuscinosis</brief_title>
	<detailed_description>This protocol design study natural disease process LINCL . We propose assess correlation genotype ( genetic constitution ) phenotype ( observable characteristic ) late infantile neuronal ceroid lipofuscinosis ( LINCL ) child diagnose LINCL stage . LINCL form Batten disease affect brain child prevents function properly . These child bear genetic change call mutation result inability brain properly recycle protein brain . The recycling failure lead death nerve cell brain progressive loss brain function . Children Batten disease normal birth age 2 4 motor vision problem progress rapidly death age approximately 10 year old . There therapies available treat disease . This study design run parallel gene transfer protocol , include 16 individual two group : Group A receive 9.0x10^11 genome copy ( gc ) vector Group B receive 2.85x10^11 gc ; anticipate able capture one-time genotype - phenotype snapshot n=32 , 18 month genotype - phenotype progression assessment n=16 .</detailed_description>
	<mesh_term>Neuronal Ceroid-Lipofuscinoses</mesh_term>
	<criteria>Inclusion Criteria . 1 . Definitive diagnosis LINCL , base clinical phenotype genotype . 2 . The subject must age 2 18 year . 3 . The subject previously participate gene transfer stem cell study . 4 . Parents study participant must agree comply good faith condition study , include attend required baseline followup assessment , parent legal guardian must give consent child 's participation . Exclusion criterion . 1 . Presence significant medical neurological condition may disqualify subject participation study e.g. , malignancy , congenital heart disease , liver renal failure . 2 . Subjects without adequate control seizures . 3 . Subjects heart disease would risk anesthesia history major risk factor hemorrhage . 4 . Subjects participate MRI study . 5 . Concurrent participation FDA approve Investigational New Drug . 6 . Subjects history prolong bleed abnormal platelet function take aspirin .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Batten Disease</keyword>
	<keyword>Late Infantile Neuronal Lipofuscinosis</keyword>
	<keyword>LINCL</keyword>
</DOC>